Literature DB >> 11037784

Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria.

E Schwartz1, G Regev-Yochay, D Kurnik.   

Abstract

Relapse of Plasmodium vivax malaria following standard primaquine dosing has been reported from many areas, and more recently from sub-Saharan Africa. In this report we describe eight episodes (in five patients) of treatment failure in non-immune Israeli travelers returning from Ethiopia. Retrospective calculation of the primaquine dose per kilogram of body weight for 23 treatment courses showed a lower total dose per kilogram in heavier patients. The mean calculated dose (95% CI) in the eight failed treatments was 2.5 +/- 0.3 mg/kg compared with 4.4 +/- 0.5 mg/kg in the 15 successful treatment courses. Weight-adjusted dosing regimens may prevent inadvertent subtherapeutic drug failure, and thus apparent primaquine failure. In these cases, no relapses were observed in those who received > 3.5 mg/kg. Consideration should be given to adjusting the dose of primaquine according to body weight. For those infected by strains from Ethiopia a dose > 3.5 mg/kg is preferable.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11037784     DOI: 10.4269/ajtmh.2000.62.393

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  18 in total

1.  Prevention and treatment of vivax malaria.

Authors:  J Kevin Baird; Eli Schwartz; Stephen L Hoffman
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

Review 2.  Resistance to therapies for infection by Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

Review 3.  Utility of 8-Aminoquinolines in Malaria Prophylaxis in Travelers.

Authors:  Eyal Meltzer; Eli Schwartz
Journal:  Curr Infect Dis Rep       Date:  2019-11-07       Impact factor: 3.725

4.  Primaquine dosing errors: the human cost of a pharmaceutical anachronism.

Authors:  Eyal Meltzer; Lindsay Morrison; Shmuel Stienlauf; Eli Schwartz
Journal:  Am J Trop Med Hyg       Date:  2015-05-11       Impact factor: 2.345

Review 5.  Primaquine in vivax malaria: an update and review on management issues.

Authors:  Deepika Fernando; Chaturaka Rodrigo; Senaka Rajapakse
Journal:  Malar J       Date:  2011-12-12       Impact factor: 2.979

6.  Diagnostic and therapeutic pitfalls associated with primaquine-tolerant Plasmodium vivax.

Authors:  Jeanne M Spudick; Lynne S Garcia; David M Graham; David A Haake
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

7.  Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia.

Authors:  Inge Sutanto; Bagus Tjahjono; Hasan Basri; W Robert Taylor; Fauziah A Putri; Rizka A Meilia; Rianto Setiabudy; Siti Nurleila; Lenny L Ekawati; Iqbal Elyazar; Jeremy Farrar; Herawati Sudoyo; J Kevin Baird
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

8.  Impact of poor-quality medicines in the 'developing' world.

Authors:  Paul N Newton; Michael D Green; Facundo M Fernández
Journal:  Trends Pharmacol Sci       Date:  2010-02-01       Impact factor: 14.819

9.  Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border.

Authors:  Rie Takeuchi; Saranath Lawpoolsri; Mallika Imwong; Jun Kobayashi; Jaranit Kaewkungwal; Sasithon Pukrittayakamee; Supalap Puangsa-art; Nipon Thanyavanich; Wanchai Maneeboonyang; Nicholas P J Day; Pratap Singhasivanon
Journal:  Malar J       Date:  2010-11-01       Impact factor: 2.979

10.  Case Report: Primaquine Failure for Radical Cure of Plasmodium vivax Malaria in Gambella, Ethiopia.

Authors:  Awash Teklehaimanot; Hailay Teklehaimanot; Abeba Girmay; Adugna Woyessa
Journal:  Am J Trop Med Hyg       Date:  2020-05-07       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.